1. Home
  2. APLM vs OXBR Comparison

APLM vs OXBR Comparison

Compare APLM & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • OXBR
  • Stock Information
  • Founded
  • APLM 2016
  • OXBR 2013
  • Country
  • APLM United States
  • OXBR Cayman Islands
  • Employees
  • APLM N/A
  • OXBR N/A
  • Industry
  • APLM Blank Checks
  • OXBR Property-Casualty Insurers
  • Sector
  • APLM Finance
  • OXBR Finance
  • Exchange
  • APLM Nasdaq
  • OXBR Nasdaq
  • Market Cap
  • APLM 6.9M
  • OXBR 16.9M
  • IPO Year
  • APLM N/A
  • OXBR 2014
  • Fundamental
  • Price
  • APLM $5.33
  • OXBR $2.21
  • Analyst Decision
  • APLM
  • OXBR Strong Buy
  • Analyst Count
  • APLM 0
  • OXBR 1
  • Target Price
  • APLM N/A
  • OXBR $5.00
  • AVG Volume (30 Days)
  • APLM 26.7K
  • OXBR 191.0K
  • Earning Date
  • APLM 08-13-2025
  • OXBR 08-07-2025
  • Dividend Yield
  • APLM N/A
  • OXBR N/A
  • EPS Growth
  • APLM N/A
  • OXBR N/A
  • EPS
  • APLM N/A
  • OXBR N/A
  • Revenue
  • APLM $198,000.00
  • OXBR $1,363,000.00
  • Revenue This Year
  • APLM $415.15
  • OXBR $497.99
  • Revenue Next Year
  • APLM N/A
  • OXBR $42.14
  • P/E Ratio
  • APLM N/A
  • OXBR N/A
  • Revenue Growth
  • APLM N/A
  • OXBR N/A
  • 52 Week Low
  • APLM $4.47
  • OXBR $1.27
  • 52 Week High
  • APLM $35.98
  • OXBR $5.81
  • Technical
  • Relative Strength Index (RSI)
  • APLM 44.49
  • OXBR 61.45
  • Support Level
  • APLM $5.33
  • OXBR $1.85
  • Resistance Level
  • APLM $6.56
  • OXBR $2.26
  • Average True Range (ATR)
  • APLM 0.54
  • OXBR 0.26
  • MACD
  • APLM -0.05
  • OXBR 0.05
  • Stochastic Oscillator
  • APLM 33.11
  • OXBR 83.33

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: